Pharmacological Management of Insomnia
Tóm tắt
Insomnia is a highly prevalent condition associated with significant morbidity, reduction in quality of life, and increase in healthcare costs, and is a risk factor for multiple physical and mental disorders. The primary treatment modality is cognitive behavioral therapy for insomnia (CBT-I) but this is associated with difficulties with access and higher cost as well as poor response in some patients. Therefore, pharmacotherapy for insomnia is common and hypnotic agents are among the most frequently prescribed medications in the United States. Older medications for insomnia are limited by their side effect burden and narrow therapeutic window. Newer hypnotics, on the other hand, have been shown to have a better safety profile and longer term efficacy. While some studies have shown that long-term hypnotic use is associated with adverse outcomes, the current evidence is equivocal. The decision to treat chronic insomnia disorder with long-term hypnotics should be individualized and balance the potential risks of continuing hypnotic medication use with the risks of untreated persistent insomnia and associated functional limitations. This clinical review discusses the currently available medication options to treat insomnia, their mechanisms of action, dosing, and side effect profiles. This review also provides guidance on long-term management of hypnotics and the use of these medications in the elderly, those with medical comorbidities, and other special populations.
Tài liệu tham khảo
Sateia MJ, Buysse DJ, Krystal AD, Neubauer DN, Heald JL. Clinical Practice Guideline for the Pharmacologic Treatment of Chronic Insomnia in Adults: An American Academy of Sleep Medicine Clinical Practice Guideline. J Clin Sleep Med, 13(2), 307-349 (2017).
Bragg S, Benich JJ, Christian N, Visserman J, Freedy J. Updates in insomnia diagnosis and treatment. Int J Psychiatry Med, 54(4-5), 275-289 (2019).
Roth T. Insomnia: definition, prevalence, etiology, and consequences. J Clin Sleep Med, 3(5 Suppl), S7-10 (2007).
Vgontzas AN, Fernandez-Mendoza J, Liao D, Bixler EO. Insomnia with objective short sleep duration: the most biologically severe phenotype of the disorder. Sleep Med Rev, 17(4), 241-254 (2013).
Ford DE, Kamerow DB. Epidemiologic study of sleep disturbances and psychiatric disorders. An opportunity for prevention? JAMA, 262(11), 1479-1484 (1989).
Khan MS, Aouad R. The Effects of Insomnia and Sleep Loss on Cardiovascular Disease. Sleep Med Clin, 12(2), 167-177 (2017).
Alvaro PK, Roberts RM, Harris JK. A Systematic Review Assessing Bidirectionality between Sleep Disturbances, Anxiety, and Depression. Sleep, 36(7), 1059-1068 (2013).
Daley M, Morin CM, LeBlanc M, Gregoire JP, Savard J. The economic burden of insomnia: direct and indirect costs for individuals with insomnia syndrome, insomnia symptoms, and good sleepers. Sleep, 32(1), 55-64 (2009).
Morgenthaler T, Kramer M, Alessi C et al. Practice parameters for the psychological and behavioral treatment of insomnia: an update. An american academy of sleep medicine report. Sleep, 29(11), 1415-1419 (2006).
Haynes J, Talbert M, Fox S, Close E. Cognitive Behavioral Therapy in the Treatment of Insomnia. South Med J, 111(2), 75-80 (2018).
Mitchell LJ, Bisdounis L, Ballesio A, Omlin X, Kyle SD. The impact of cognitive behavioural therapy for insomnia on objective sleep parameters: A meta-analysis and systematic review. Sleep Med Rev, 47, 90-102 (2019).
Spielman AJ, Caruso LS, Glovinsky PB. A behavioral perspective on insomnia treatment. Psychiatr Clin North Am, 10(4), 541-553 (1987).
Schwartz MD, Kilduff TS. The Neurobiology of Sleep and Wakefulness. Psychiatr Clin North Am, 38(4), 615-644 (2015).
Vazquez-DeRose J, Schwartz MD, Nguyen AT et al. Hypocretin/orexin antagonism enhances sleep-related adenosine and GABA neurotransmission in rat basal forebrain. Brain Struct Funct, 221(2), 923-940 (2016).
Inouye ST, Kawamura H. Persistence of circadian rhythmicity in a mammalian hypothalamic "island" containing the suprachiasmatic nucleus. Proceedings of the National Academy of Sciences, 76(11), 5962-5966 (1979).
Morin CM, Bélanger L, LeBlanc M et al. The natural history of insomnia: a population-based 3-year longitudinal study. Arch Intern Med, 169(5), 447-453 (2009).
Balter MB, Uhlenhuth EH. New epidemiologic findings about insomnia and its treatment. J Clin Psychiatry, 53 Suppl, 34-39; discussion 40-32 (1992).
National Institutes of Health State of the Science Conference statement on Manifestations and Management of Chronic Insomnia in Adults, June 13-15, 2005. Sleep, 28(9), 1049-1057 (2005).
Krystal AD, Erman M, Zammit GK, Soubrane C, Roth T, Group ZS. Long-term efficacy and safety of zolpidem extended-release 12.5 mg, administered 3 to 7 nights per week for 24 weeks, in patients with chronic primary insomnia: a 6-month, randomized, double-blind, placebo-controlled, parallel-group, multicenter study. Sleep, 31(1), 79-90 (2008).
Krystal AD, Walsh JK, Laska E et al. Sustained efficacy of eszopiclone over 6 months of nightly treatment: results of a randomized, double-blind, placebo-controlled study in adults with chronic insomnia. Sleep, 26(7), 793-799 (2003).
Kripke DF. Mortality Risk of Hypnotics: Strengths and Limits of Evidence. Drug Saf, 39(2), 93-107 (2016).
Neutel CI, Johansen HL. Association between hypnotics use and increased mortality: causation or confounding? Eur J Clin Pharmacol, 71(5), 637-642 (2015).
Osler M, Jørgensen MB. Associations of Benzodiazepines, Z-Drugs, and Other Anxiolytics With Subsequent Dementia in Patients With Affective Disorders: A Nationwide Cohort and Nested Case-Control Study. Am J Psychiatry, 177(6), 497-505 (2020).
Shamim SA, Warriach ZI, Tariq MA, Rana KF, Malik BH. Insomnia: Risk Factor for Neurodegenerative Diseases. Cureus, 11(10), e6004 (2019).
Farkas RH, Unger EF, Temple R. Zolpidem and driving impairment--identifying persons at risk. N Engl J Med, 369(8), 689-691 (2013).
Greenblatt DJ, Harmatz JS, Roth T. Zolpidem and Gender: Are Women Really At Risk? J Clin Psychopharmacol, 39(3), 189-199 (2019).
Mindell JA, Cook RA, Nikolovski J. Sleep patterns and sleep disturbances across pregnancy. Sleep Med, 16(4), 483-488 (2015).
Okun ML, Ebert R, Saini B. A review of sleep-promoting medications used in pregnancy. Am J Obstet Gynecol, 212(4), 428-441 (2015).
Black RA, Hill DA. Over-the-counter medications in pregnancy. Am Fam Physician, 67(12), 2517-2524 (2003).
Ancoli-Israel S, Krystal AD, McCall WV et al. A 12-week, randomized, double-blind, placebo-controlled study evaluating the effect of eszopiclone 2 mg on sleep/wake function in older adults with primary and comorbid insomnia. Sleep, 33(2), 225-234 (2010).
Walsh JK, Soubrane C, Roth T. Efficacy and safety of zolpidem extended release in elderly primary insomnia patients. Am J Geriatr Psychiatry, 16(1), 44-57 (2008).
Ancoli-Israel S, Walsh JK, Mangano RM, Fujimori M. Zaleplon, A Novel Nonbenzodiazepine Hypnotic, Effectively Treats Insomnia in Elderly Patients Without Causing Rebound Effects. Prim Care Companion J Clin Psychiatry, 1(4), 114-120 (1999).
Roth T, Seiden D, Sainati S, Wang-Weigand S, Zhang J, Zee P. Effects of ramelteon on patient-reported sleep latency in older adults with chronic insomnia. Sleep Med, 7(4), 312-318 (2006).
Krystal AD, Durrence HH, Scharf M et al. Efficacy and Safety of Doxepin 1 mg and 3 mg in a 12-week Sleep Laboratory and Outpatient Trial of Elderly Subjects with Chronic Primary Insomnia. Sleep, 33(11), 1553-1561 (2010).
Sys J, Van Cleynenbreugel S, Deschodt M, Van der Linden L, Tournoy J. Efficacy and safety of non-benzodiazepine and non-Z-drug hypnotic medication for insomnia in older people: a systematic literature review. Eur J Clin Pharmacol, 76(3), 363-381 (2020).
Ong JC, Crawford MR. Insomnia and Obstructive Sleep Apnea. Sleep Med Clin, 8(3), 389-398 (2013).
Eckert DJ, Owens RL, Kehlmann GB et al. Eszopiclone increases the respiratory arousal threshold and lowers the apnoea/hypopnoea index in obstructive sleep apnoea patients with a low arousal threshold. Clin Sci (Lond), 120(12), 505-514 (2011).
Heinzer RC, White DP, Jordan AS et al. Trazodone increases arousal threshold in obstructive sleep apnoea. Eur Respir J, 31(6), 1308-1312 (2008).
Angarita GA, Emadi N, Hodges S, Morgan PT. Sleep abnormalities associated with alcohol, cannabis, cocaine, and opiate use: a comprehensive review. Addict Sci Clin Pract, 11(1), 9 (2016).
Kolla BP, Mansukhani MP, Biernacka J, Chakravorty S, Karpyak VM. Sleep disturbances in early alcohol recovery: Prevalence and associations with clinical characteristics and severity of alcohol consumption. Drug Alcohol Depend, 206, 107655 (2020).
Kolla BP, Mansukhani MP, Schneekloth T. Pharmacological treatment of insomnia in alcohol recovery: a systematic review. Alcohol Alcohol, 46(5), 578-585 (2011).
Vandrey R, Smith MT, McCann UD, Budney AJ, Curran EM. Sleep disturbance and the effects of extended-release zolpidem during cannabis withdrawal. Drug Alcohol Depend, 117(1), 38-44 (2011).
Liang L, Huang Y, Xu R, Wei Y, Xiao L, Wang G. Eszopiclone for the treatment of primary insomnia: a systematic review and meta-analysis of double-blind, randomized, placebo-controlled trials. Sleep Medicine, 62, 6-13 (2019).
Chen LF, Lin CE, Chou YC, Mao WC, Chen YC, Tzeng NS. A comparison of complex sleep behaviors with two short-acting Z-hypnosedative drugs in nonpsychotic patients. Neuropsychiatr Dis Treat, 9, 1159-1162 (2013).
Griffin CE, 3rd, Kaye AM, Bueno FR, Kaye AD. Benzodiazepine pharmacology and central nervous system-mediated effects. Ochsner J, 13(2), 214-223 (2013).
Morris HH, III, Estes ML. Traveler's Amnesia: Transient Global Amnesia Secondary to Triazolam. JAMA, 258(7), 945-946 (1987).
Juhl RP, Daugherty VM, Kroboth PD. Incidence of next-day anterograde amnesia caused by flurazepam hydrochloride and triazolam. Clin Pharm, 3(6), 622-625 (1984).
Clark JW, Brian ML, Drummond SPA, Hoyer D, Jacobson LH. Effects of orexin receptor antagonism on human sleep architecture: A systematic review. Sleep Med Rev, 53, 101332 (2020).
Rhyne DN, Anderson SL. Suvorexant in insomnia: efficacy, safety and place in therapy. Ther Adv Drug Saf, 6(5), 189-195 (2015).
Kuriyama A, Tabata H. Suvorexant for the treatment of primary insomnia: A systematic review and meta-analysis. Sleep Med Rev, 35, 1-7 (2017).
Rosenberg R, Murphy P, Zammit G et al. Comparison of Lemborexant With Placebo and Zolpidem Tartrate Extended Release for the Treatment of Older Adults With Insomnia Disorder: A Phase 3 Randomized Clinical Trial. JAMA Netw Open, 2(12), e1918254 (2019).
Goforth HW. Low-dose doxepin for the treatment of insomnia: emerging data. Expert opinion on pharmacotherapy, 10(10), 1649-1655 (2009).
Yeung W-F, Chung K-F, Yung K-P, Ng TH-Y. Doxepin for insomnia: A systematic review of randomized placebo-controlled trials. Sleep Medicine Reviews, 19, 75-83 (2015).
Lankford A, Rogowski R, Essink B, Ludington E, Heith Durrence H, Roth T. Efficacy and safety of doxepin 6mg in a four-week outpatient trial of elderly adults with chronic primary insomnia. Sleep Medicine, 13(2), 133-138 (2012).
Stahl SM. Mechanism of action of trazodone: a multifunctional drug. CNS spectrums, 14(10), 536-546 (2009).
Jaffer KY, Chang T, Vanle B et al. Trazodone for Insomnia: A Systematic Review. Innov Clin Neurosci, 14(7-8), 24-34 (2017).
James SP, Mendelson WB. The use of trazodone as a hypnotic: a critical review. J Clin Psychiatry, 65(6), 752-755 (2004).
Mendelson WB. A review of the evidence for the efficacy and safety of trazodone in insomnia. J Clin Psychiatry, 66(4), 469-476 (2005).
Roth AJ, McCall WV, Liguori A. Cognitive, psychomotor and polysomnographic effects of trazodone in primary insomniacs. Journal of sleep research, 20(4), 552-558 (2011).
Warner MD, Peabody CA, Whiteford HA, Hollister LE. Trazodone and priapism. Journal of Clinical Psychiatry, 48(6), 244-245 (1987).
Arendt J, Skene DJ. Melatonin as a chronobiotic. Sleep Medicine Reviews, 9(1), 25-39 (2005).
Ferracioli-Oda E, Qawasmi A, Bloch MH. Meta-analysis: melatonin for the treatment of primary sleep disorders. PLoS One, 8(5), e63773 (2013).
Erland LA, Saxena PK. Melatonin Natural Health Products and Supplements: Presence of Serotonin and Significant Variability of Melatonin Content. J Clin Sleep Med, 13(2), 275-281 (2017).
Kuriyama A, Honda M, Hayashino Y. Ramelteon for the treatment of insomnia in adults: a systematic review and meta-analysis. Sleep Med, 15(4), 385-392 (2014).
Leach MJ, Page AT. Herbal medicine for insomnia: A systematic review and meta-analysis. Sleep Med Rev, 24, 1-12 (2015).
Sateia MJ, Buysse DJ, Krystal AD, Neubauer DN, Heald JL. Clinical Practice Guideline for the Pharmacologic Treatment of Chronic Insomnia in Adults: An American Academy of Sleep Medicine Clinical Practice Guideline. J Clin Sleep Med, 13(2), 307-349 (2017).